Navigation Links
New Data for Abbott's Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
Date:7/30/2013

HOUSTON, July 30, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay presented at this year's American Association for Clinical Chemistry (AACC) annual meeting in Houston, Texas. The study, conducted by researchers at Brigham and Women's Hospital, demonstrated that Abbott's hsTnI test (currently for research-use only in the United States) may help doctors predict which patients presenting with symptoms of a heart attack, such as severe chest pain, are at a higher risk for having a heart attack 30 days later.

A concern for patients who present with severe chest pain is that they are more likely to experience another cardiovascular event within a few weeks or months. Researchers at Brigham and Women's Hospital evaluated the performance of a hsTnI assay (Abbott, ARCHITECT) with the performance of a fourth generation troponin T assay (Roche, TnT) among 4,695 patients presenting with severe chest pain and found that the hsTnI assay identified more patients at higher risk of recurrent heart attack, even at very low troponin concentrations.

"The ability to identify patients at higher risk for another heart attack or cardiovascular death is an essential step in their prevention," said Dr. Petr Jarolim, M.D., Ph.D., one of the key authors of the study and Medical Director, Clinical Chemistry and Laboratory Control, Brigham and Women's Hospital. "This study demonstrates that the new high sensitivity cardiac troponin assays are efficient tools for classifying patients, allowing doctors to provide more aggressive treatment of those at higher risk."

Cardiac troponin, a protein found in the heart muscle,
'/>"/>

SOURCE Abbott
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
2. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
3. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
4. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
5. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
6. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
7. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
8. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... CHAPEL HILL, N.C. , Aug. 29, 2014 /PRNewswire/ ... the face of regulatory and marketplace changes. CI leaders ... flounder. In a new Best Practices, ... a host of actionable insights, including: - ... and cheaper than primary research - Internal ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... Owner Pleads Guilty; Dog Wardens Revoke,Snyder County Kennel ... officials are cracking down on unsatisfactory kennels with ... prosecutor and dog,wardens, Special Deputy Agriculture Secretary for ... dog wardens continue to make progress enforcing current,regulations. ...
... Corp.,(Nasdaq: GENZ ) announced today that the ... trial examining the safety and effectiveness of,Clolar(R) (clofarabine) ... leukemia (AML) who are unlikely to benefit from ... to provide substantial,evidence for expanding the current product ...
Cached Medicine Technology:Dog Law Officers' Crackdown on Unsatisfactory Kennels Protecting Animals, Consumers 2Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 2Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 3Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 4Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 5Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML 6
(Date:8/30/2014)... Franklin, TN (PRWEB) August 30, 2014 ... techniques, including nine mobilizations and six muscle energy techniques. ... also narrates and demonstrates twenty-seven examination techniques for the ... course supports Dr. Reiman's live course presentation with ... Objectives, Applying a differential diagnosis ...
(Date:8/30/2014)... Celebrating its 25th year, Recovery Month ... the fact that millions of Americans lives have ... addiction and mental health disorders. Every September ... programs and other community groups to recognize the ... The rallying theme for Substance Abuse and ...
(Date:8/30/2014)... Barcelona, Spain Saturday 30 August 2014: The first ... They are presented at ESC Congress 2014 by Task ... Aboyans (France). , The "2014 ESC Guidelines on the ... online in European Heart Journal (1) ... "Previous ESC recommendations were published in 2001 but they ...
(Date:8/29/2014)... Daily Gossip writes in its review that ... market nowadays. This method promises to teach readers how to ... some effective alternative sources for the production of energy. ... wind and solar power. , The Home Made Energy ... an eBook. So, this is an online guide that will ...
(Date:8/29/2014)... MD (PRWEB) August 30, 2014 AGH ... by the Doctors in Delaware at Atlantic ... of free health-related services. In addition to no-cost blood ... Maryland offers first aid care at local sports tournaments. ... and other medical staff provide free disease management and ...
Breaking Medicine News(10 mins):Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 2Health News:September is National Recovery Month: What the Connecticut Community for Addiction Recovery (CCAR) Wants You to Know 3Health News:First comprehensive ESC Guidelines on aortic diseases published 2Health News:First comprehensive ESC Guidelines on aortic diseases published 3Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... New Jersey medical malpractice attorney David A. Mazie of Mazie Slater Katz ... history for a 47-year old man rendered legally blind as a result ... Russo. , ... Roseland, NJ (PRWEB) July 9, 2006 -- ...
... part of uKarma,s vertical integration strategy and will, ... complementary health and wellness brands, LOS ANGELES, ... a lifestyle multimedia and consumer products company,focused on ... Xflowsion studio will open in Southern California in ...
... Wrong on Veterans Health Care, WASHINGTON, July ... Employees (AFGE) launched a nationwide radio ad,campaign raising ... care. In addition to the radio ads, AFGE, ... launched a Web site, http://www.fundtheva.com, and a ...
... extended backorder from the manufacturer, Wedgewood Pharmacy will compound this ... suspension in the most frequently prescribed strengths. Acepromazine will be ... ... SWEDESBORO, N.J. (Business Wire EON) July ...
... Summer and ... Throughout the Year, PINELLAS PARK, Fla., July 9 ... its effects on the skin, many,are not aware that the eyes are ... and Transitions Optical found that nearly 80,percent of consumers report knowing that ...
... WASHINGTON, July 9 Updates on the impact ... MRSA infections,and the importance of childhood immunizations were ... Press Club in Washington, D.C. The news,conference, sponsored ... addressed the growing challenge of prevention and treatment ...
Cached Medicine News:Health News:$2.1 Million Lasik Malpractice Settlement Against Celebrity Physician Dr. Joseph Dello Russo 2Health News:uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel 2Health News:Union Representing VA Workers Launch Nationwide Radio Campaign, Web Site and Viral Videos for Full VA Funding 2Health News: Wedgewood Pharmacy Responds to Acepromazine Maleate Drug Shortage 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 3Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 2Health News:Public Health Experts Provide Update on Current Infectious Diseases Threats 3
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: